Selection of Products. WJPF shall decide which of the Products it wishes to distribute through the Designated Distributor in the PRC pursuant to the specific distribution agreements to be concluded in accordance with this Agreement and notify BRIDGETECH the Products in writing. The above-mentioned notice shall, in addition to the specific Product or Products, include the structure (either trading or profit-sharing structure) that WJPF and the Designated Distributor will adopt in distributing the Product.
Selection of Products. Subject to Section 3.3.3(b), with respect to the First Generation FocalGel Product or the First Generation Radiopharmaceutical Product or any of the first three Second Generation Products, if in the judgment of the Developing Party such product demonstrates efficacy, including without limitation demonstration of efficacy in a pig or other mutually agreed upon large animal model, the Developing Party shall use reasonable commercial efforts to conduct Product Development of the Product in question, at the Developing Party's sole expense. Focal shall be informed with respect to such Product Development. Focal agrees to provide reasonable mutually agreed technical support as reasonably necessary pursuant to the Research Plan and Budget; however, except as otherwise expressly agreed in writing, Focal shall have no obligation to perform pre-clinical studies other than those contained in the Research Plan and Budget or clinical studies or other portions of Product Development. It is understood during the term of this Agreement, the Developing Party may select a Product for Product Development at any time.
Selection of Products. Development Candidates will become Products upon the filing of an IND for such Development Candidate, which filing will be made only after the JSC determines that such Development Candidate is suitable for clinical trials based on its preclinical profile and competitive and other commercial considerations.
Selection of Products. For each Development Candidate, during the Late Clinical Development Term and following review of the data from activities under the applicable Early Clinical Development Plan and Late Clinical Development Plan, the JSC will decide whether such Development Candidate should be selected as a Product for Commercialization pursuant to a Joint Commercialization Plan in accordance with the terms and conditions of this Agreement. If, following the review of data from activities under the applicable Early Clinical Development Plan and Late Clinical Development Plan, the JSC does not agree whether such Development Candidate is appropriate for selection as a Product, then a Party may exercise its Opt-Out Right with respect to such Development Candidate and associated Product in accordance with Section 3.2.
Selection of Products. (a) The Lead Products shall be the first Products that the Parties plan to Develop, Finalize, Manufacture and Commercialize pursuant to this Agreement.
(b) From time to time before the tenth (10th) anniversary of the First Commercial Sale of the first Product, either Party may present to the JSC another potential Compound Construct as a potential Product that the Parties may consider Developing, Finalizing, Manufacturing and Commercializing. With respect to the consideration of any potential Product, each Party shall present such material information it possesses regarding Development, Final Development, Manufacture and Commercialization opportunities, risks and costs. Each Party shall consider the information presented to the JSC with respect to each potential Product and, when requested by the other Party, shall determine whether such potential Product will be selected as a Product under this Agreement. Unless and until such Party selects such potential Product as a Product, it shall not be considered a Product under this Agreement and neither Party shall have any obligation to the other Party with respect to such potential Product under this Agreement, except to the extent provided in Sections 3.1(c) and 3.2 below.
Selection of Products. New Product Ideas will be selected for representation on the basis of their potential to solve a problem, uniqueness, whether their benefits are easy to understand, patentability, product sales potential and product market size. Any New Product Idea deemed to be tasteless, objectionable or otherwise unacceptable for any reason whatsoever to EUREKA may be excluded from consideration in the sole discretion of EUREKA and nothing contained herein shall be deemed an agreement or commitment by Eureka to represent the Inventor or any New Product Idea. • By signing this Agreement, the Inventor hereby grants EUREKA an exclusive ninety (90) day period of time to review and evaluate the New Product Idea (the “Review Period”). The Inventor shall not and shall require each of his or her representatives and agents not to, during the Review Period, directly or indirectly,
Selection of Products. 3.1.1 The Parties have agreed upon the Initial Collaboration Programs as of the Effective Date. At any time during the Program Selection Period, Regeneron shall have the option to nominate up to [***] additional Collaboration Programs, each focused on identifying Products which may include a combination of particular [***] for inclusion under this Agreement (such Collaboration Program, an “Additional Collaboration Program,” and such option, an “Additional Collaboration Program Option”).
3.1.2 Regeneron shall submit each proposed Tumor Target and Effector Moiety combination for a potential Additional Collaboration Program to the Gatekeeper. The Gatekeeper will determine the Availability of such Tumor Target and Effector Moiety combination in accordance with the following procedure. CytomX and the Gatekeeper shall maintain an up-to-date list of Tumor Targets and Effector Moieties that are not Available, until the Program Selection Period expires. Prior to nominating a Tumor Target and Effector Moiety combination, Regeneron’s Alliance Manager shall notify CytomX’s Alliance Manager via email of Xxxxxxxxx’s intent to submit a Tumor Target and Effector Moiety combination to the Gatekeeper. CytomX shall have up to [***] Business Days after such notification by Xxxxxxxxx’s Alliance Manager to confirm that the Gatekeeper’s list of Tumor Targets and Effector Moieties that are not Available is current (and shall inform Xxxxxxxxx’s Alliance Manager promptly upon such confirmation). Regeneron shall notify the Gatekeeper in writing via email on a confidential basis of its intention to determine whether one or more Tumor Targets and Effector Moieties are Available, at which point the Gatekeeper shall provide written notice to Regeneron via email as to whether such proposed Tumor Target(s) and Effector Moiety(ies) is Available or not Available, but the identity of such proposed Tumor Target and Effector Moiety shall not be disclosed to CytomX. If such proposed Tumor Target and Effector Moiety are both Available, and Xxxxxxxxx wishes to select such proposed Tumor Target and Effector Moiety combination for an Additional Collaboration Program, it shall notify CytomX in writing of its selection within [***] Business Days (the “Additional Collaboration Program Notice”). Upon CytomX’s receipt of an Additional Collaboration Program Notice from Regeneron, such Additional Collaboration Program shall be deemed a Collaboration Program under this Agreement, and the Product Selection ...
Selection of Products. The Decorcafe will be working in partnership with our members to select products and present them in a way that will be most appealing to our community. We set a consistent high-quality standard for the products for sale and the way in which they are presented. It is essential for the benefit of all our members that a high level of professionalism and quality is maintained. We will only invite, accept and retain products in the Decorcafe shop that conform to the highest levels of quality and service. The Decorcafe shop is a curated collection, where a carefully selected number of products are presented.
Selection of Products. New Product Ideas will be selected for representation on the basis of their potential to solve a problem, uniqueness, whether their benefits are easy to understand, patentability, product sales potential and product market size. Any New Product Idea deemed to be tasteless, objectionable or otherwise unacceptable to ADI may be excluded from consideration in the sole discretion of ADI. After submitting a New Product Idea, the Inventor will grant ADI an exclusive sixty (60) day period of time to review and evaluate the New Product Idea. If after the review period ADI accepts the New Product Idea, then ADI will ask the inventor to enter into a Representation Agreement with ADI. If ADI does not accept the New Product Idea by the end of the 60-day period, then all rights in the New Product Idea will revert to the Inventor and ADI shall have no further rights whatsoever in the New Product Idea. Inventors will be notified whether their New Product Idea(s) have been selected for representation by ADI. If ADI has elected to pursue the idea, the Inventor will be asked to sign a Representation Agreement or a Licensing Agreement. Inventors entering into a Representation Agreement will grant ADI a period of one hundred and eighty (180) days to represent the Inventor’s New Product Idea for the purpose of ADI’s seeking potential manufacturers to enter into licensing contracts for the use of the New Product Idea. The details of ADI’s representation are more specifically described in the Representation Agreement. If ADI hasn’t licensed or commercialized the New Product Idea by the end of the 180-day period, ADI will terminate all of its rights, interest and obligations granted to it by the Inventor with respect to the New Product Idea.
Selection of Products. 31 4.5 Conduct of the Research Program.............................................................................. 32 4.6 Funding of the Research Program.............................................................................. 32 4.6.1 Pre-Development Expenses............................................................................... 32 4.6.2
